undamentalytics Newsletter
Sign in

Xeris Biopharma Holdings, Inc. (XERS) stock

Add to watchlist

Add holding +

NASDAQ: XERS Nasdaq Pharmaceuticals Next results ~November 5, 2026

C Fundamentals grade

Xeris Biopharma Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($0.04) was left out of our combined valuation (it is 0.00x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Price vs value

Under review: our cash-flow value ($0.04) was left out of our combined valuation (it is 0.00x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating. We'll show the comparison once resolved.

Xeris Biopharma Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 33 sales by directors and officers, last 12 monthsInsider trades
  • Funds136 adding, 91 cuttingOf 47 active managers that changed their stake, 26 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Xeris Biopharma Holdings files

Where Xeris Biopharma stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $335m, up 36.3% on a year earlier, slower than the 41.5% growth a quarter earlier. That growth ranks 3 of 34 among the pharmaceuticals companies we cover. Free-cash-flow margin rose to 16.5% from -7.1% a year earlier. Operating margin widened to 10.9% from -4.0%. The diluted share count is up 19.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 5 financial-health checks.

Our model value for Xeris Biopharma Holdings is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Xeris Biopharma Holdings, Inc.'s trailing-twelve-month revenue grew 36.3% year on year, with a free-cash-flow margin of 16.5%. Where it stands out: revenue growth of 36.3% ranks 14 of 74 pharmaceuticals companies we cover. Where it lags: change in share count of 19.6% ranks 53 of 62 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$0.0 per share in the base case (—–$0.3 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 172% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 36.3% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Margins widening. Operating margin is up 14.9 points on a year ago.

Things to watch

  • Growth slowing. The growth rate is 5.1 points lower than a quarter earlier.
  • Share dilution. Diluted shares rose 19.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 54% and a beta of 0.9 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 45.8% ranks 42 of 53 pharmaceuticals companies we cover (median 23.8%).
  • Below peers: stock pay as % of revenue. Stock pay as % of revenue of 8.4% ranks 52 of 69 pharmaceuticals companies we cover (median 3.6%).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.00 against an average estimate of $0.00: missed by 172.0%
Revenue
$92m, up 28.7% on a year earlier
Share reaction
-2.2% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate $0.03

Xeris Biopharma Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.5%
  • 1 week-0.3%
  • 1 month+14.8%
  • This year+29.6%
  • 1 year+5.3%
  • 5 years+437.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$335M
Operating margin
10.9%
Net margin
-5.1%
EPS (TTM, diluted)
$-0.09

Growth

Revenue growth
+36.3%
Change in growth rate
−5.1 pts
Share count change
+19.6%

Cash

Free cash flow (TTM)
$55.3M
FCF margin
16.5%
Stock pay % of revenue
8.4%

Earnings

Last results
August 6, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Announcement
  4. Results
  5. Share issue

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Xeris Biopharma Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($0.04) was left out of our combined valuation (it is 0.00x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Our value per share comes from a discounted-cash-flow model of Xeris Biopharma Holdings, Inc.'s free cash flow after stock-based pay ( $2.9M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Xeris Biopharma Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.96 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$0.0 Left out: out of range vs price (0.00x)
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.7 ~$1.5–$3.6 Included
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.7 ~$1.8–$3.3 Left out: out of range vs price (0.17x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Xeris Biopharma Holdings, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$4.92$2.93$1.33$2.35$3.39$7.85$10.17
Market value$210m$232m$180m$324m$498m$1.4bn$1.9bn
+ Net debt (− = net cash)$49m$21m$75m$131m$177m$123m$131m
Enterprise value$259m$252m$256m$455m$675m$1.5bn$2.0bn
Multiples
Price / sales 10.3x4.7x1.6x2.0x2.5x4.6x5.5x
Price / earnings —————n/m—
Price / free cash flow —————47.4x—
EV / EBITDA —————56.4x52.4x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

15 /100

Weak moat

How hard Xeris Biopharma Holdings's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -18.0% of total assets over 5 years.

  • Durability 10 / 20

    Operating margin has been a median -33.8%; its worst year was -223.2%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 5 years, at a median -21.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (20 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $102m and EPS of $0.03 (range $0.01 to $0.04) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.09 0% $388m +33%
Next $0.20 +319% $480m +24%

Next year's EPS estimate has moved −50.2% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −163.2% on 90 days ago. In the last 30 days, 0 analysts raised Xeris Biopharma Holdings, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Xeris Biopharma Holdings, Inc., last 90 days
−$0.20 $0.00 $0.20 $0.40 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.14 Current fiscal year, 60 days ago: $0.07 Current fiscal year, 30 days ago: −$0.04 Current fiscal year, 7 days ago: −$0.08 Current fiscal year, Now: −$0.09 −$0.09 Next fiscal year, 90 days ago: $0.40 Next fiscal year, 60 days ago: $0.38 Next fiscal year, 30 days ago: $0.27 Next fiscal year, 7 days ago: $0.22 Next fiscal year, Now: $0.20 $0.20

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.14$0.40
60 days ago $0.07$0.38
30 days ago −$0.04$0.27
7 days ago −$0.08$0.22
Now −$0.09$0.20

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.00 −$0.00 −172.0%
Mar 2026 −$0.00 $0.01 +1592.5%
Dec 2025 $0.04 $0.06 +33.3%
Sept 2025 $0.00 $0.00 −100.0%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Xeris Biopharma Holdings, Inc.'s revenue by +25.7% next year and +20.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+29.5%, weight 60%) and the company's own record (+20.0%, weight 40%) . How the weights are set.

Analyst recommendations

7 analysts, Oct 2026
Buy686%
Hold114%
Sell00%

Monthly trend

  1. Oct 20261517
  2. Sep 20261517
  3. Aug 20261517
  4. Jul 20261517

Counts of recommendations published by analysts covering Xeris Biopharma Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.6%
of tradable shares
Days to cover
2.46
at average volume
Short interest, 1 month
−0%
to October 15, 2026
Held by institutions
61%
of shares
Held by insiders
3.0%
of shares
Employees
435
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +4.8%

$9.70 on October 31, 2025 to $10.17

ThenNowEffect
Revenue (last 12 months) $246m $335m +36.3%
P/S multiple 6.0x 5.5x −8.0%
Share count 153m 182m −16.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +435.3%

$1.90 on November 3, 2023 to $10.17

ThenNowEffect
Revenue (last 12 months) $134m $335m +150.2%
P/S multiple 1.9x 5.5x +185.6%
Share count 137m 182m −25.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
XERS−40%−55%+77%+44%+132%+30%
Industry peers (median)−18%−49%−14%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
XERS42%33%58%75%75%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
XERS−76%−61%−51%−47%−35%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 21, 2018: 96% from September 10, 2018 to January 5, 2023. Getting back needed a 2544% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.29 – $11.13
From 52-week high
−8.6%
vs 50-day average
+8.9%
vs 200-day average
+35.4%
Volatility (1 year)
54%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±8.9%
After a week
8 up, 4 down
typical move ±13.3%
After a month
7 up, 5 down
typical move ±12.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −2.2% +0.5% +2.7% +5.2%
May 7, 2026 +2.5% +0.5% +0.2% −2.0%
March 2, 2026 −2.9% −0.8% −8.5% −5.2%
January 8, 2026 +10.0% +0.7% +2.8% −3.5%
November 6, 2025 −24.7% −1.0% −26.4% −29.2%
August 7, 2025 +24.6% +0.7% +33.0% +41.5%
May 8, 2025 +11.8% +0.6% +6.9% 0.0%
March 6, 2025 +12.5% −1.2% +21.0% +17.0%
January 10, 2025 −2.4% −1.4% −4.8% +6.0%
November 8, 2024 −2.4% +0.5% −13.1% +6.5%
August 8, 2024 +8.9% +2.8% +23.0% +25.4%
July 8, 2024 +2.4% +0.2% +17.5% +7.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Xeris Biopharma Holdings, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Xeris Biopharma Holdings, Inc.
$150M $200M $250M $300M $350M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $152.7M Revenue (TTM), FY23 Q4: $163.9M Revenue (TTM), FY24 Q1: $171.4M Revenue (TTM), FY24 Q2: $181.4M Revenue (TTM), FY24 Q3: $187.4M Revenue (TTM), FY24 Q4: $203.1M Revenue (TTM), FY25 Q1: $222.6M Revenue (TTM), FY25 Q2: $246M Revenue (TTM), FY25 Q3: $266.1M Revenue (TTM), FY25 Q4: $291.8M Revenue (TTM), FY26 Q1: $314.9M Revenue (TTM), FY26 Q2: $335.4M $335.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $152.7M
FY23 Q4 $163.9M
FY24 Q1 $171.4M
FY24 Q2 $181.4M
FY24 Q3 $187.4M
FY24 Q4 $203.1M
FY25 Q1 $222.6M
FY25 Q2 $246M
FY25 Q3 $266.1M
FY25 Q4 $291.8M
FY26 Q1 $314.9M
FY26 Q2 $335.4M
Revenue growth, TTM YoY Xeris Biopharma Holdings, Inc.
20% 30% 40% 50% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 54.9% Revenue growth, TTM YoY, FY23 Q4: 48.7% Revenue growth, TTM YoY, FY24 Q1: 41.2% Revenue growth, TTM YoY, FY24 Q2: 35.3% Revenue growth, TTM YoY, FY24 Q3: 22.7% Revenue growth, TTM YoY, FY24 Q4: 23.9% Revenue growth, TTM YoY, FY25 Q1: 29.9% Revenue growth, TTM YoY, FY25 Q2: 35.6% Revenue growth, TTM YoY, FY25 Q3: 42.0% Revenue growth, TTM YoY, FY25 Q4: 43.7% Revenue growth, TTM YoY, FY26 Q1: 41.5% Revenue growth, TTM YoY, FY26 Q2: 36.3% 36.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 54.9%
FY23 Q4 48.7%
FY24 Q1 41.2%
FY24 Q2 35.3%
FY24 Q3 22.7%
FY24 Q4 23.9%
FY25 Q1 29.9%
FY25 Q2 35.6%
FY25 Q3 42.0%
FY25 Q4 43.7%
FY26 Q1 41.5%
FY26 Q2 36.3%
Operating margin (TTM) Xeris Biopharma Holdings, Inc.
-40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -32.3% Operating margin (TTM), FY23 Q4: -26.8% Operating margin (TTM), FY24 Q1: -26.2% Operating margin (TTM), FY24 Q2: -20.5% Operating margin (TTM), FY24 Q3: -24.1% Operating margin (TTM), FY24 Q4: -16.6% Operating margin (TTM), FY25 Q1: -10.1% Operating margin (TTM), FY25 Q2: -4.0% Operating margin (TTM), FY25 Q3: 3.7% Operating margin (TTM), FY25 Q4: 8.5% Operating margin (TTM), FY26 Q1: 11.4% Operating margin (TTM), FY26 Q2: 10.9% 10.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -32.3%
FY23 Q4 -26.8%
FY24 Q1 -26.2%
FY24 Q2 -20.5%
FY24 Q3 -24.1%
FY24 Q4 -16.6%
FY25 Q1 -10.1%
FY25 Q2 -4.0%
FY25 Q3 3.7%
FY25 Q4 8.5%
FY26 Q1 11.4%
FY26 Q2 10.9%
FCF margin (TTM) Xeris Biopharma Holdings, Inc.
-60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -47.2% FCF margin (TTM), FY23 Q4: -29.6% FCF margin (TTM), FY24 Q1: -24.9% FCF margin (TTM), FY24 Q2: -21.6% FCF margin (TTM), FY24 Q3: -17.5% FCF margin (TTM), FY24 Q4: -18.8% FCF margin (TTM), FY25 Q1: -12.5% FCF margin (TTM), FY25 Q2: -7.1% FCF margin (TTM), FY25 Q3: 3.5% FCF margin (TTM), FY25 Q4: 9.4% FCF margin (TTM), FY26 Q1: 15.0% FCF margin (TTM), FY26 Q2: 16.5% 16.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -47.2%
FY23 Q4 -29.6%
FY24 Q1 -24.9%
FY24 Q2 -21.6%
FY24 Q3 -17.5%
FY24 Q4 -18.8%
FY25 Q1 -12.5%
FY25 Q2 -7.1%
FY25 Q3 3.5%
FY25 Q4 9.4%
FY26 Q1 15.0%
FY26 Q2 16.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 20 50 110 164 203 292 335
EBITDA −82 −114 −81 −43 −32 26 38
Operating income −84 −115 −82 −44 −34 25 37
Net income −91 −123 −95 −62 −55 1 −17
Diluted EPS −$2.14 −$1.55 −$0.70 −$0.45 −$0.37 $0.00 −$0.09
Growth (year on year)
Revenue — +142.7% +122.3% +48.7% +23.9% +43.7% +36.3%
Margins
EBITDA margin −401.7% −229.5% −73.1% −25.9% −16.0% 9.0% 11.3%
Operating margin −408.8% −232.2% −74.3% −26.8% −16.6% 8.5% 10.9%
Net margin −446.0% −247.5% −85.9% −38.0% −27.0% 0.2% −5.1%
Free-cash-flow margin −396.1% −194.8% −93.3% −28.7% −18.2% 9.8% —
Cash flow
Cash from operations −81 −96 −103 −47 −37 29 57
Capital spending 0 1 0 0 0 0 —
Free cash flow −81 −97 −103 −47 −37 29 —
Stock-based pay 8 11 12 11 18 22 28
Free cash flow after stock pay −89 −108 −115 −58 −55 6 —
Balance sheet
Cash 38 67 122 67 72 111 122
Total debt 87 88 197 199 249 234 253
Net debt (negative = net cash) 49 21 75 131 177 123 131
Diluted shares 43m 79m 136m 138m 147m 173m 182m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 5 checks passed · June 30, 2026
What it owns · $412m
Short-term assets $275mLonger-term assets $137m
What it owes, and who funded it · $422m
Short-term liabilities $190mLonger-term liabilities $232mShareholders' equity $-10m
  • Short-term assets cover short-term liabilities $275m of assets due within a year against $190m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $275m short-term assets against $232m of longer-dated liabilities.
  • More cash than debt $122m of cash against $253m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $57m of operating cash flow against $253m of debt.
  • Operating profit covers interest at least five times over Operating income of $37m against $28m of interest.

From Xeris Biopharma Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+19.6%
year over year
R&D spending
10.4%
of revenue
Sales & admin spending
62.1%
of revenue
Days sales outstanding
63 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated XERS EOLS IRWD HROW INVA ACB Median
Revenue, last 12 months $335m $316m $389m $276m $440m $232m $276m
Revenue growth, last 12 months 36.3% 13.9% 26.2% 21.1% 18.8% 11.7% 9.9%
Revenue growth, 3-year average 35.8% 23.4% −3.1% 39.0% 14.9% — 5.5%
Revenue growth, latest quarter 28.7% 21.2% 32.6% 10.9% 19.3% — 6.5%
Gross margin — 66.7% 99.2% 73.3% 72.2% 42.6% 62.0%
Operating margin 10.9% −5.9% 60.1% −1.0% 36.9% 1.9% −5.9%
Operating margin, 3-year average −4.5% −12.6% 37.4% −0.1% 59.6% — −7.4%
Net margin −5.1% −10.8% 33.4% −13.5% 81.2% −42.4% −7.3%
Cash from operations / revenue 16.9% −4.9% 47.7% 2.3% 43.5% −4.2% 10.2%
Free-cash-flow margin 16.5% −5.8% 47.7% 1.8% 43.1% −5.4% 8.6%
Free-cash-flow margin, 3-year average −4.1% −9.6% 31.3% 0.8% 48.3% — 7.4%
Stock pay / revenue 8.4% 6.6% 3.7% 5.3% 2.8% 2.3% 3.6%
Change in share count 19.6% 2.3% −2.0% 0.5% 18.0% 3.0% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 36.3% 10.0% 14 of 74
Change in growth rate Growth -5.1pp -0.3pp 51 of 74
Operating margin Profitability 10.9% -5.9% 21 of 67
Net margin Profitability -5.1% -7.3% 36 of 75
Free-cash-flow margin Cash generation 16.5% 10.1% 29 of 74
Stock pay as % of revenue Cash generation 8.4% 3.6% 52 of 69
Long-term debt as % of assets Balance sheet 45.8% 23.8% 42 of 53
Change in share count Balance sheet 19.6% 1.5% 53 of 62
Days sales outstanding Balance sheet 63 days 72 days 21 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $283M 97.0% ▲ 43.9%
Recorlev $139M 49.2% ▲ 116.7%
Gvoke $94.1M 33.3% ▲ 13.6%
Keveyis $47.6M 16.8% ▼ 3.8%
Product Other $2M 0.7% —
Royalty Contract and Other Revenue $8.8M 3.0% ▲ 37.4%

From Xeris Biopharma Holdings, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$855M
Institutions reporting
238
Shares held vs prior quarter
▲ 2.9%
Positions opened / closed
32 / 26

Top buyers and sellers, Q2 2026: 136 institutions bought and 91 sold ; the biggest buyer was Blackrock, Inc (+1.6M shares) and the biggest seller Millennium Management LLC (−2.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $115M 14.5M 13.5% ▲ 12.2%
D. E. Shaw & Co., Inc. $61.8M 7.8M 7.2% ▲ 0.2%
Vanguard Capital Management LLC $58.1M 7.3M 6.8% ▲ 5.1%
State Street Corp $38.2M 4.8M 4.5% ▲ 3.5%
Geode Capital Management, LLC $37.4M 4.7M 4.4% ▲ 10.0%
Nuveen, LLC $34.7M 4.4M 4.1% ▲ 50.4%
Rosalind Advisors, Inc. $23M 2.9M 2.7% ▼ 10.0%
Qube Research & Technologies Ltd $22.9M 2.9M 2.7% ▼ 29.7%
Vanguard Portfolio Management LLC $20.8M 2.6M 2.4% ▼ 1.5%
Wellington Management Group LLP $18.7M 2.4M 2.2% ▲ 8.9%
Morgan Stanley $18.5M 2.3M 2.2% ▼ 9.2%
Legal & General Group PLC $15.9M 2.0M 1.9% ▲ 5.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Xeris Biopharma Holdings, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $5.4M 33 trades by 9 insiders · 82% under pre-set plans
Net ▼ $5.4M net selling
Insider Date Trade Shares Price Value
Hecht Beth See Remarks October 1, 2026 Sell pre-set plan 16,666 $9.41 $156,792
Mcculloch Kevin See Remarks October 1, 2026 Sell pre-set plan 15,000 $9.41 $141,120
Pieper Steven See Remarks October 1, 2026 Sell pre-set plan 5,000 $9.41 $47,036
Mcculloch Kevin See Remarks September 28, 2026 Sell pre-set plan 25,000 $10.00 $250,000
Pieper Steven See Remarks September 1, 2026 Sell pre-set plan 5,000 $8.50 $42,500
Hecht Beth See Remarks September 1, 2026 Sell pre-set plan 16,666 $8.49 $141,494
Mcculloch Kevin See Remarks September 1, 2026 Sell pre-set plan 15,000 $8.49 $127,350
Pieper Steven See Remarks August 12, 2026 Sell pre-set plan 5,000 $8.50 $42,500
Hecht Beth See Remarks August 3, 2026 Sell pre-set plan 16,666 $8.01 $133,495
Mcculloch Kevin See Remarks August 3, 2026 Sell pre-set plan 15,000 $8.02 $120,300
Pieper Steven See Remarks July 7, 2026 Sell pre-set plan 27,600 $8.52 $235,152
Pieper Steven See Remarks July 6, 2026 Sell pre-set plan 17,400 $8.50 $147,900

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • May 7, 2026
  • March 2, 2026
  • January 8, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Xeris Biopharma Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Xeris Biopharma Holdings, Inc. in brief

What does Xeris Biopharma Holdings, Inc. do?
Xeris Biopharma Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Xeris Biopharma Holdings, Inc.'s stock ticker?
Xeris Biopharma Holdings, Inc. trades under the ticker XERS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Xeris Biopharma Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Xeris Biopharma Holdings, Inc. reported revenue of $335M, 36.3% higher than a year earlier, according to its SEC filings.
What is Xeris Biopharma Holdings, Inc.'s free cash flow?
Xeris Biopharma Holdings, Inc.'s free-cash-flow margin is 16.5% of revenue over the trailing twelve months, ranking 29 of the 74 pharmaceuticals companies we cover.
Who are Xeris Biopharma Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., D. E. Shaw & Co., Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Xeris Biopharma Holdings, Inc.'s market cap?
On November 2, 2026, Xeris Biopharma Holdings, Inc.'s market capitalisation was about $1.9B and net debt of $131M. Market figures come from third-party market data and may be delayed.
Who are Xeris Biopharma Holdings, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Xeris Biopharma Holdings, Inc. are Evolus, Inc., Ironwood Pharmaceuticals Inc, Harrow, Inc., Innoviva, Inc. and Aurora Cannabis Inc. The side-by-side comparison below sets their revenue, margins and growth against Xeris Biopharma Holdings, Inc.'s.
Are insiders buying or selling Xeris Biopharma Holdings, Inc. stock?
Over the last 12 months, Xeris Biopharma Holdings, Inc.'s directors and officers reported 0 open-market purchases and 33 sales on Form 4. The insider trading page charts every trade.
When is Xeris Biopharma Holdings, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Xeris Biopharma Holdings, Inc. announces its own schedule.